Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locall
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the
| Condition(s) | Papillary Renal Cell Carcinoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024. |
| Who can participate | Inclusion Criteria: Patients must meet all the following criteria to be included in the real-world cohort: 1. Age ≥ 18 years at the index date 2. One of the following: 1)diagnosed with unresectable and locally advanced, or metastatic PRCC; 2)diagnosed with unresectable and locally advanced, or metastatic RCC, and with papillary (papillary ≥ 50%) as the dominant and presumed primary histology type. 3.Patients who received 1L therapy of sunitinib or sorafenib 4.Patients with tumor assessment or relevant clinical visit within 6-month follow-up since index date. (The rationale and details of 6-month minimal follow-up is presented in section 3.6). Death events within 6-month will be included. Exclusion Criteria: Patients who meet one or more following criteria will be excluded from the real-wor |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2025-03-31 |
| NCT ID | NCT07024680 |
| Official listing | https://clinicaltrials.gov/study/NCT07024680 |